Screener
Corcept Therapeutics CORT EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax (expense) benefit | (2,944) | 3,457 | 10,010 | 14,386 |
| Net income | 42,987 | 35,149 | 11,226 | 55,696 |
| Net income attributable to common stockholders | 42,141 | 34,611 | 11,017 | 54,918 |
| Basic net income per common share | $0.40 | $0.33 | $0.11 | $0.53 |
| Diluted net income per common share | $0.36 | $0.29 | $0.09 | $0.46 |
| Weighted-average shares outstanding used in computing net income per common share | ||||
| Basic | 105,377 | 104,111 | 104,909 | 104,108 |
| Diluted | 118,385 | 120,485 | 116,373 | 120,227 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's EPS (diluted)?
- Corcept Therapeutics (CORT) reported EPS (diluted) of $0.36 in Q2 2026.
- How has Corcept Therapeutics's EPS (diluted) changed year-over-year?
- Corcept Therapeutics's EPS (diluted) increased by 24.1% year-over-year, from $0.29 to $0.36.
- What is the long-term trend for Corcept Therapeutics's EPS (diluted)?
- Over 4 years (2021 to 2025), Corcept Therapeutics's EPS (diluted) has grown at a -2.0% compound annual growth rate (CAGR), from $0.89 to $0.82.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Corcept Therapeutics's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude